Premium
Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL)
Author(s) -
Leupin Nicolas,
Cenni Bruno,
Novak Urban,
Hügli Barbary,
Graber Hans U.,
Tobler Andreas,
Fey Martin F.
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04227.x
Subject(s) - pten , loss of heterozygosity , chronic lymphocytic leukemia , cancer research , tumor suppressor gene , biology , allele , b cell , gene , genetics , leukemia , carcinogenesis , antibody , pi3k/akt/mtor pathway , apoptosis
Summary. One fifth of B‐cell chronic lymphocytic leukaemia (B‐CLL) patients exhibit loss of heterozygosity (LOH) at 10q23.3, the site of the tumour suppressor PTEN. Microsatellite markers mapped complete LOH to 10q23.3 in 2/41 B‐CLL (5%) and allelic imbalances in 6/41 (15%). No PTEN gene mutations were found. PTEN protein expression was not detected in 11 B‐CLL (28%), and was reduced in eight patients (20%). LOH or allelic imbalances at 10q23.3 were fairly frequent in B‐CLL, but did not encompass the PTEN gene. Nevertheless, PTEN protein may be absent in B‐CLL with a normal PTEN genotype, suggesting a role of this phosphatase in the molecular pathology of B‐CLL.